数据统计显示，中证沪港深张江自主创新50指数近一个月下跌6.62%，近三个月上涨7.11%，年至今上 涨10.05%。 据了解，中证沪港深张江自主创新50指数从沪港深三地市场中选取50只业务涉及生物医药、集成电路、 人工智能、高端装备制造、节能环保、新材料等产业的张江高新区上市公司证券作为指数样本，以反映 沪港深三地市场张江高新区新兴产业上市公司证券的整体表现。该指数以2014年12月31日为基日，以 1000.0点为基点。 中证沪港深张江自主创新50指数上涨0.03%，前十 大权重包含中芯国际等 从中证沪港深张江自主创新50指数持仓样本的行业来看，信息技术占比67.98%、医药卫生占比 20.15%、工业占比6.75%、通信服务占比2.12%、原材料占比1.69%、房地产占比0.89%、可选消费占比 0.42%。 金融界3月24日消息，上证指数上涨0.15%，中证沪港深张江自主创新50指数 (SHS张江50，931596)上涨 0.03%，报1485.13点，成交额293.43亿元。 从指数持仓来看，中证沪港深张江自主创新50指数十大权重分别为：韦尔股份（11.04%）、中芯国际 （9.85%）、中微公司（ ...

车： 思宇MedTech | MedRobot | 心未来 | 眼未来 | 骨未来 | 探美医界 | 医影像 寻求报道，请联系Alice：suribot21 投稿/订制报告，请联系主编： qingzhao2017 学院 SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE 第十期 MEDICAL AND HEALTH FUTURE LEADING TALENTS 多重 8年 300位 医健同侪印证启迪 课程送代积淀 思维破茧和能力跃迁 号MedTech 全球最新医疗科技动态 66 这里有独具价值的 医健生态圈层 THERE IS A VALUABLE MEDICAL AND HEALTH ECOSYSTEM HERE 变局时代企业家思维破茧 全面打通产学研用 解锁医疗产业未来 成就卓越领军人才 我们面临的问题无比复杂, 您需要站在更高的平台, 洞察趋势,明确方向,做出取舍, 统合行动,聚拢资源, 成为医疗产业未来的合格舵手! NOLILIA VALUE 课程价值 上海交通大学医学院拥有: 日 | 13家附属医院 R 21位院士 201 t+ 转化医学国家重大科技基础 ...

证券代码：688271 证券简称：联影医疗 公告编号：2025-005 上海联影医疗科技股份有限公司 股东询价转让结果报告书暨持股 5%以上股东 持有权益比例降至 5%以下的权益变动提示性公告 上海中科道富投资合伙企业（有限合伙）（以下简称"中科道富"）、上海北元 投资合伙企业（有限合伙）（以下简称"北元投资"）（以下合称"转让方"）保证向 上海联影医疗科技股份有限公司（以下简称"公司"、"上市公司"、"联影医疗"） 提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、 准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的价格为 108.66 元/股，转让的股票数量为 29,086,400 股。 公司控股股东、实际控制人、董事、监事及高级管理人员不参与本次询 价转让。 本次转让不会导致公司控股股东、实际控制人发生变化。 本次权益变动后，中科道富及其一致行动人持股比例持股比例由 8.52922% 减少至 4.99999%，持有权益比例将至 5%以下。 一、 转让方情况 (一)转让方基本情况 截至 2025 年 3 ...

股票代码：688271 上市公司名称：上海联影医疗科技股份有限公司 股票简称：联影医疗 股票上市地点：上海证券交易所 五、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务 人外，没有委托或者授权任何其他人提供未在本报告中列载的信息和对本报告 做出任何解释或者说明。 六、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗 漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 信息披露义务人1：上海中科道富投资合伙企业（有限合伙） 住所及通讯地址：中国(上海)自由贸易试验区临港新片区环湖西二路888号C楼 信息披露义务人2：上海北元投资合伙企业（有限合伙） 住所及通讯地址：中国(上海)自由贸易试验区临港新片区环湖西二路888号C楼 股份变动性质：股份减少（询价转让） 签署日期：2025年3月21日 1 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与 格式准则第15号——权益变动报告书》及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共 ...

中国国际金融股份有限公司 关于上海联影医疗科技股份有限公司 股东向特定机构投资者询价转让股份的核查报告 中国国际金融股份有限公司（以下简称"中金公司""组织券商"）受上海联影 医疗科技股份有限公司（以下简称"联影医疗""公司""上市公司"）股东上海中 科道富投资合伙企业（有限合伙）（以下简称"中科道富"）、上海北元投资合伙企 业（有限合伙）（以下简称"北元投资"）（以下合称"出让方"）委托，组织实施 本次联影医疗股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 经核查，中金公司就本次询价转让的出让方、受让方是否符合《上海证券交易所 科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询价转让 和配售指引》"）要求，本次询价转让的询价、转让过程与结果是否公平、公正，是 否符合《询价转让和配售指引》的规定作出如下报告说明。 一、本次询价转让概述 （一）本次询价转让出让方 截至2025年3月14日，出让方所持公司股份的数量、比例情况如下： | 出让方名称 | 截至2025年3月14日收盘持股数量（股） | 持股比例 | | --- | --- | --- | | 中科道富 | 41,46 ...

Core Viewpoint - The Shanghai Stock Exchange (SSE) is actively conducting a large-scale research initiative on private enterprises, focusing on how these companies are embracing artificial intelligence (AI) technology to enhance their operations and competitiveness [1][2]. Group 1: AI Integration in Private Enterprises - Private enterprises listed on the Shanghai Stock Exchange are proactively integrating AI technologies, with companies like Fosun Pharma leveraging global leading AI models to enhance drug development processes [4]. - Fosun Pharma has launched the PharmAID decision-making AI platform, which addresses various challenges in drug research, including literature review and market analysis [4]. - Dragon Flag Technology is focusing on AI/AR smart glasses as a key growth area, indicating a significant shift towards AI-driven products in the consumer electronics sector [5][6]. Group 2: Research and Development Insights - The SSE's research initiative aims to identify the main challenges faced by private enterprises and explore how capital market tools can help overcome these obstacles [2][9]. - Companies have expressed the need for expanded AI databases and reduced financing costs to enhance AI applications in their operations [9]. - Fosun Pharma's Vice Chairman highlighted the necessity of increasing data volume for effective AI training in drug development [9]. Group 3: Growth of Private Enterprises in Shanghai - Private enterprises constitute over 50% of the companies listed on the Shanghai Stock Exchange, with a total market value of approximately 14 trillion yuan [12]. - In the first three quarters of 2024, private enterprises in Shanghai achieved a revenue of 5.37 trillion yuan, with a compound annual growth rate of 8.7% over the past three years [12]. - The investment in R&D by these enterprises reached 193.5 billion yuan, reflecting a compound annual growth rate of 13.4% [12].

Summary of Conference Call on Union Medical and Yirui Technology Industry and Company Overview - **Industry**: Medical Imaging Equipment - **Companies**: Union Medical (联影医疗) and Yirui Technology (奕瑞科技) Key Points and Arguments Union Medical's Market Position and Performance - Union Medical has a comprehensive product line in the medical imaging equipment sector, including diagnostic, therapeutic devices, and life science instruments, leading the domestic market with over 120 products and a presence in over 13,700 medical institutions, including more than 1,000 top-tier hospitals [3][4] - The company achieved a compound annual growth rate (CAGR) of 41% in revenue from 2018 to 2023, but faces pressure in 2024 due to fluctuations in downstream demand, with expectations of recovery in 2025 [3][4] - Revenue structure shows that 89% comes from equipment sales, while maintenance and software services account for only 11%, indicating significant room for growth in recurring revenue compared to international leaders like Siemens, which has a 50% recurring revenue ratio [3][4] - Approximately 80% of sales revenue is generated from mainland China, with rapid growth in overseas markets, making international expansion a key growth driver [3][4] - The company maintains high gross and net profit margins, with a non-GAAP net profit margin of 15%, significantly higher than General Electric's margin of less than 10% [3][4] Management Team and Governance - The management team is experienced, with many executives having backgrounds in Siemens or GE, providing technical and industry expertise [5] - The actual controller, Xuan Ming, and the Shanghai State-owned Assets Supervision and Administration Commission are shareholders, positively influencing corporate governance [5] - The company has implemented a restricted stock incentive plan with a target of 20% CAGR in revenue, reflecting confidence in future growth [5] Competitive Landscape - The global medical imaging equipment market is highly concentrated, with Siemens, Union Medical, GE, and Philips holding over 75% of the MRI market share [7][8] - Union Medical's product line offers both breadth and depth, catering to various market segments from traditional X-ray to advanced MRI [9] Yirui Technology's Market Position - Yirui Technology is a leader in the X-ray detector market with a global market share of 20%, expanding into core components like tubes and high-voltage generators for future growth [3][20] - The company may face performance pressure in 2024 but has significant long-term potential due to increasing downstream medical and industrial demand and the trend of domestic substitution [3][20] Government Policies and Market Trends - The Ministry of Finance's draft on government procurement favors domestic products, potentially enhancing the development of domestic components and encouraging multinational companies to consider domestic suppliers [3][29] - The domestic medical equipment market is rapidly growing, with high-end equipment demand increasing, supported by relaxed policies for high-end medical equipment configuration [16] Future Outlook - Both Union Medical and Yirui Technology are positioned in high-barrier industries with clear competitive advantages, expected to perform well despite short-term demand fluctuations [41] - Anticipated recovery in 2025, particularly in the medical sector, with significant growth potential in overseas markets for Union Medical [19][41] Risks - Potential risks include lower-than-expected downstream demand, challenges in new business development, and litigation risks involving subsidiaries, although current legal outcomes are not expected to have a significant impact [40] This summary encapsulates the key insights from the conference call regarding Union Medical and Yirui Technology, highlighting their market positions, management strengths, competitive landscapes, and future growth prospects.

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Views - The pharmaceutical sector is experiencing a digital transformation and intelligent upgrade, with AI expected to significantly impact drug development, medical imaging, multi-omics diagnostics, and healthcare services [37][36]. - The report emphasizes the importance of high-quality R&D innovation as the core driver of the pharmaceutical industry, with a focus on innovative drugs and medical devices [37][36]. - The report suggests that the recent market shift has led to increased support for innovative drugs, with policies expected to further bolster the sector [37][36]. Market Performance - The overall A-share market rose by 1.36%, with the pharmaceutical and biotechnology sector increasing by 1.77%, outperforming the broader market [27][27]. - Specific segments within the pharmaceutical sector showed varied performance, with the medical commercial sector leading with a 6.44% increase [27][27]. Key Companies and Investment Recommendations - The report recommends several companies with strong growth potential, including: - Mindray Medical (迈瑞医疗): A leader in domestic medical devices benefiting from new infrastructure and product upgrades [39]. - United Imaging Healthcare (联影医疗): Focused on high-performance medical imaging equipment and expanding into international markets [39]. - WuXi AppTec (药明康德): A comprehensive drug development service platform poised to benefit from the global outsourcing market [39]. - New Industries (新产业): A leader in chemiluminescence immunoassay with strong growth prospects [39]. - Aikang Medical (爱康医疗): A low-valuation leader in the medical consumables sector [37][39]. Clinical Data and Innovations - The report highlights recent clinical data from the American Academy of Dermatology (AAD) meeting, showcasing advancements in psoriasis treatments, particularly focusing on TYK2 inhibitors [2][20]. - Notable products include: - Icotrokinra by Johnson & Johnson, showing significant efficacy in clinical trials [14][21]. - ICP-488 by Innovent Biologics, demonstrating promising results in Phase II trials [17][21]. - D-2570 by Eifang Biotech, also showing strong efficacy in clinical trials [20][21]. Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is reported at 31.76x, compared to the overall A-share market at 18.46x [33][33]. - Specific sub-sectors show varied P/E ratios, with chemical pharmaceuticals at 36.94x and medical services at 38.31x [33][33].

Investment Rating - The report initiates coverage with a "Buy" rating for the company, with a target price of RMB 194.39, indicating a potential upside of 54% from the current price of RMB 126.54 [1][6][26]. Core Insights - The company is positioned to benefit from a comprehensive product line in medical imaging, challenging the dominance of imported brands in the Chinese market. The product lines include CT, MR, XR, MI, and RT, with significant market shares in previously monopolized segments [6][20][40]. - The company is expected to experience a revenue CAGR of 14.2% from 2023 to 2026, driven by technological advancements and policy support, despite facing short-term impacts in 2024 [6][22][24]. - The overseas business has shown strong growth, with revenue reaching RMB 9.33 billion in the first half of 2024, a 29.9% increase year-on-year, indicating the company's expanding international influence [7][23]. - The report highlights the company's focus on R&D innovation, with significant investments leading to the launch of groundbreaking products, such as the world's first 5T whole-body clinical MR [24][25]. Financial Summary - The company's revenue is projected to grow from RMB 10.26 billion in 2024 to RMB 16.98 billion in 2026, with net profit expected to rise from RMB 1.26 billion to RMB 2.88 billion during the same period [8][22]. - The earnings per share (EPS) estimates for 2024, 2025, and 2026 are RMB 1.52, RMB 2.62, and RMB 3.50, respectively, reflecting a positive growth trajectory [2][8]. Market Context - The Chinese medical imaging equipment market is projected to grow at a CAGR of 10.9% from 2019 to 2023, with the CT segment holding the largest market share at 32% in 2023 [29][30]. - The report emphasizes the increasing demand for high-end medical imaging equipment driven by an aging population and rising health awareness, which is expected to sustain market growth [33][34].

Investment Rating - The report initiates coverage with a "Buy" rating for the company, with a target price of RMB 194.39, indicating a potential upside of 54% from the current price of RMB 126.54 [1][2][26] Core Views - The company is positioned to benefit from technological advancements and policy support, leading to significant growth in the medical imaging equipment market. The report anticipates a recovery in the company's performance starting in 2025, with a projected revenue CAGR of 14.2% from 2023 to 2026 [6][9][22] - The company has a comprehensive product line in medical imaging, including CT, MR, XR, MI, and RT, which allows it to compete effectively against established international brands in China [6][40] - The report highlights the company's strong market position, particularly in CT and MR products, with significant revenue contributions expected from these segments in the coming years [6][24][43] Summary by Sections Financial Performance - The company reported revenues of RMB 11.41 billion in 2023, with projections of RMB 10.26 billion for 2024, RMB 13.80 billion for 2025, and RMB 16.98 billion for 2026. The net profit is expected to decline to RMB 1.26 billion in 2024 before recovering to RMB 2.16 billion in 2025 and RMB 2.88 billion in 2026 [8][22][24] - The estimated EPS for 2024, 2025, and 2026 are RMB 1.52, RMB 2.62, and RMB 3.50 respectively, reflecting a recovery trajectory post-2024 [2][8] Market Position and Growth Drivers - The company has established a strong foothold in the domestic market, with a leading market share in CT products and significant positions in MR and MI segments. The report notes that the company is well-positioned to capitalize on the trend of domestic substitution in the medical imaging market [6][43][40] - The report emphasizes the company's global expansion strategy, with overseas revenue reaching RMB 9.33 billion in the first half of 2024, marking a 29.9% year-on-year increase, and accounting for 17.5% of total revenue [7][23] Product Line and Innovation - The company offers a wide range of medical imaging products, including advanced CT and MR systems, which are expected to drive future revenue growth. The report highlights the introduction of innovative products such as the uMR Jupiter 5T and uLinac HalosTx, which are set to enhance the company's competitive edge [6][24][25] - The report projects that the company's CT product line will experience a revenue CAGR of -4.6% in 2024, followed by a recovery with 18.2% and 13.6% growth in 2025 and 2026 respectively. The MR product line is expected to grow significantly, with a projected CAGR of 24.4% from 2024 to 2026 [6][24][25]